For the quarter ending 2025-06-30, VRNA made $103,138K in revenue. $11,921K in net income. Net profit margin of 11.56%.
| Income Statement | 2025-06-30 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenue, net | 103,138 | 12,212 | 5,624 | |
| Research and development | 12,950 | 11,144 | 10,552 | |
| Cost of sales | 4,756 | 680 | 543 | |
| Selling, general and administrative | 72,127 | 38,185 | 35,196 | |
| Total operating expenses | 89,833 | 50,205 | 46,291 | |
| Operating income/(loss) | 13,305 | -37,987 | -40,667 | |
| Foreign exchange gain(loss) | - | - | 1,475 | |
| Research and development tax credit | 0 | 1,185 | 1,612 | |
| Interest expense | - | - | 9,882 | |
| Interest income | 4,302 | 3,504 | 4,750 | |
| Interest expense | 6,822 | 5,886 | - | |
| Loss on extinguishment of debt | 0 | -913 | - | |
| Foreign exchange gain/(loss) | 1,097 | -42 | - | |
| Total other (expense)/income, net | -1,423 | -2,152 | -2,045 | |
| Income/(loss) before income taxes | 11,882 | -40,139 | -42,712 | |
| Income tax benefit/(expense) | -39 | 3,346 | 250 | |
| Net income/(loss) | 11,921 | -43,485 | -42,962 | |
| Profit/(loss) per share, basic (in dollars per share) | 0.02 | -0.067 | -0.07 | |
| Profit/(loss) per share, diluted (in dollars per share) | 0.02 | -0.067 | -0.07 | |
| Weighted-average shares outstanding, basic (in shares) | 685,155,000 | 122,194 | 651,944,000 | |
| Weighted-average shares outstanding, diluted (in shares) | 727,223,000 | 122,194 | 651,944,000 | |
Verona Pharma plc (VRNA)
Verona Pharma plc (VRNA)